Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry. Oncol Rep. 2019 May 03;: Authors: Wu M, Sun Q, Mo CH, Pang JS, Hou JY, Pang LL, Lu HP, Dang YW, Fang SJ, Tang D, Chen G, Feng ZB Abstract Breast cancer (BC) has a complex etiology and pathogenesis, and is the most common malignant tumor type in females, in USA in 2018, yet its relevant molecular mechanisms remain largely unknown. The collagen type V α‑1 chain (COL5A1) gene is differentially expressed in renal and ovarian cancer. Using bioinformatics methods, COL5A1 was determined to also be a significant gene in BC, but its association with BC has not been sufficiently reported. COL5A1 microarray and relevant clinical data were collected from the Gene Expression Omnibus, The Cancer Genome Atlas and other databases to summarize COL5A1 expression in BC and its subtypes at the mRNA and protein levels. All associated information was comprehensively analyzed by various software. The clinical significance of the mutation was obtained via the cBioPortal. Furthermore, Gene Ontology functional annotation and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were also performed to investigate the mechanism of COL5A1 in BC. Immunohistochemistry was also conducted to detect and confirm COL5A1 expression. It was determined that COL5A1 was highly expressed in BC tissues, compared with normal tissues at the mRNA level [st...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

(Northwestern University) Many of the deadliest or most common cancers get the least amount of nonprofit research funding, reports a new Northwestern Medicine study. 'Embarrassing' or stigmatized cancers, like lung and liver, are underfunded. Colon, endometrial, liver and bile duct, cervical, ovarian, pancreatic and lung cancers were all poorly funded compared to how common they are and how many deaths they cause, the study found. In contrast, breast cancer, leukemia, lymphoma and pediatric cancers were all well-funded, respective to their impact on society.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion.Our data showed a low prevalence of the BRCA1/2 founder mutations in Colombians of African descent, implying that these mutations should not be recommended for genetic screening programs in the Afro‐Colombian population.Implications for Practice.Risk reduction intervention programs are needed for women who are found to carry a BRCA1/2 mutation, as is the implementation of prevention programs for patients with inherited breast cancer, to reduce the burden of inherited diseases. With the aim of reducing racial disparities in breast cancer prevention, this study focused on genetic testing and treatment for patien...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer, Global Health and Cancer Source Type: research
Abstract Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor genes over two decades ago, a significant amount of research has been done. Most recently, monoallelic loss-of-function mutations in PALB2 have also been shown to increase the risk of breast cancer. The identification of BRCA1, BRCA2 and PALB2 as proteins involved in DNA double-strand break repair by homologous recombination and of the impact of complete loss of BRCA1 or BRCA2 within tumors have allowed the development of novel therapeutic appro...
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Background Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline BRCA mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy. Methods This is a biomarker analysis including young (≤40 years) early breast cancer patients with known germline BRCA mutational status and available prospectively collected frozen plasma samples before and after chemotherapy. Chemotherapy consisted of either six cycles of FEC (5 fluorouracil ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis study suggests that ovarian stimulation in patients with early stage breast cancer is safe in the long term.
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
Abstract Members of the ABC transporter family, particularly P-glycoprotein (P-gp, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance protein 1 (MRP1, ABCC1) are well characterized mediators of multidrug resistance, however their pharmacological inhibition has so far failed as a clinical strategy. Harnessing collateral sensitivity, a form a synthetic lethality where cells with acquired multidrug resistance exhibit hypersensitivity to unrelated agents, may be an alternative approach to targeting multidrug resistant tumour cells. We characterized a novel small molecule modulator that sel...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
CONCLUSIONS: The implementation of gene panels using NGS in the study of hereditary cancer involves the detection of heterozygous double mutations in genes of high and moderate penetrance for cancer, although with a low frequency. PMID: 31292799 [PubMed - as supplied by publisher]
Source: Clin Med Res - Category: Research Authors: Tags: Breast Cancer Res Treat Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
(University of Alberta Faculty of Medicine&Dentistry) New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(University of Birmingham) Research has found important new ways that the BRCA1 gene functions which could help develop our understanding of the development of ovarian and breast cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Ovarian Cancer | Ovaries